Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.
These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.
Here’s what you may have missed:
FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC: Alexander B. Olawaiye, MD
Alexander B. Olawaiye, MD, of the University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, discusses the March 2026 FDA approval of relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens including at least 1 bevacizumab (Avastin)-containing regimen, supported by data from the phase 3 ROSELLA trial (NCT05257408). In ROSELLA, patients who received the combination (n = 188) experienced significant improvements in progression-free survival (PFS; HR, 0.70; 95% CI, 0.54-0.91; P = .0076) and overall survival (OS; HR, 0.65; 95% CI, 0.51-0.83; P = .0004) vs nab-paclitaxel alone (n = 193). Olawaiye emphasized that the decision is particularly clinically meaningful because ROSELLA examined the combination in a non–biomarker-selected patient population, making it available to a wider group of patients vs other approvals in this space that carry biomarker constraints. The prescribing information includes a contraindication for patients requiring corticosteroids for lifesaving indications, along with warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions, and embryo-fetal toxicity.
Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma: Alex Herrera, MD
Alex Herrera, MD, of City of Hope, discusses the significance of the March 2026 FDA approval of nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (AVD) for use in patients with previously untreated stage III or IV classical Hodgkin lymphoma. The decision is supported by results from the phase 3 CA209-8UT/SWOG 1826 study (NCT03907488). The trial showed that median PFS outcomes significantly favoring nivolumab plus AVD over brentuximab vedotin (Adcetris) plus AVD (HR, 0.42; 95% CI, 0.27-0.67; P < .0001), with 3-year follow-up data presented at the 2025 ASH Annual Meeting and Exposition showing a 3-year PFS rate of 91% (95% CI, 88%-93%) vs 82% (95% CI, 78%-85%; HR, 0.48; 95% CI, 0.34-0.69; P < .0001) in the nivolumab (n = 487) and brentuximab vedotin (n = 483) arms, respectively. The combination was well tolerated, with serious adverse effects (AEs) and grade 3 or 4 immune-mediated AEs occurring at rates of 39% and 2.7%, respectively, in the nivolumab arm. Herrera concluded that these data position nivolumab plus AVD as a new standard of care in the frontline setting for those with advanced-stage classical Hodgkin lymphoma.
Landmark Efficacy Data With Daraxonrasib in Previously Treated Metastatic PDAC: Shubham Pant, MD, MBBS
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses results from the phase 3 RASolute 302 trial (NCT06625320) examining daraxonrasib (RMC-6236) in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring RAS mutations, including G12D, G12V, and G12R. An interim analysis revealed that daraxonrasib produced statistically significant and clinically meaningful improvements in both PFS and OS vs standard chemotherapy. Patients who received daraxonrasib achieved a median OS of 13.2 months compared with 6.7 months in those given chemotherapy (HR, 0.40; P < .0001). The agent had a manageable safety profile, and no new safety signals were observed. These data, which will be presented at the 2026 ASCO Annual Meeting, are complemented by phase 1/2 results (NCT05379985; NCT06445062) exploring daraxonrasib as monotherapy and in combination with nab-paclitaxel (Abraxane) and gemcitabine in the frontline setting. The agent is also under investigation in frontline metastatic PDAC as part of the phase 3 RASolute-303 trial (NCT07491445). Pant characterized these findings as historic and practice-changing for both academic and community oncologists—the most impactful data since the comparison of FOLFIRINOX against gemcitabine over a decade ago—and concluded that daraxonrasib marks a new era in precision medicine for PDAC.
Raising Awareness for Skin Cancer in Light of Melanoma Monday: Neil D. Gross, MD, FACS
Neil D. Gross, MD, FACS, of The University of Texas MD Anderson Cancer Center, discusses the importance of year-round vigilance in skin cancer prevention and education in recognition of Skin Cancer Awareness Month and Melanoma Monday. Despite widespread public health campaigns, many patients remain unaware that melanoma can be linked to ultraviolet (UV) exposure that occurred years or even decades earlier, highlighting a persistent and critical gap in public understanding of cumulative sun damage and its role in cancer development. Gross emphasized that increasing awareness of risk factors, particularly intermittent and chronic sun exposure, must be paired with education on early warning signs like changes in the size, shape, or color of moles, as early detection remains one of the most effective ways to improve outcomes, given that melanoma is significantly more treatable when identified at an early stage. He concluded that consistent sun-protective behaviors such as sunscreen use, protective clothing, and avoidance of peak UV hours are critical not only for individuals today but for safeguarding future generations, and that sustained education and behavioral change beyond awareness campaigns are needed to reduce the overall burden of skin cancer.
Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis: Andrew Kuykendall, MD
Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses considerations for JAK inhibitor sequencing and the role of transplant in myelofibrosis, presented at the 2026 Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma meeting. Although allogeneic stem cell transplant remains the only potentially curative option for patients with myelofibrosis, its substantial morbidity and mortality make timing decisions particularly complex, as patients experiencing meaningful improvements in symptom burden, splenomegaly, and quality of life on JAK inhibitor therapy are less inclined to pursue transplant, despite that period potentially representing an optimal disease-management window for the procedure. Regarding JAK inhibitor sequencing among the 4 FDA-approved agents, Kuykendall advocated moving away from a rigid frontline/second-line framework in favor of individualizing therapy based on patient-specific needs, citing anemia management as one example where clinicians might transition from ruxolitinib (Jakafi) to momelotinib (Ojjaara) and potentially back based on symptom control. He concluded that optimal timing of transplant referral and intervention remains the biggest unanswered question in this space, and that current JAK inhibitor selection is best guided by matching the most appropriate agent to each individual patient rather than adhering to a predefined sequencing algorithm.
